Home
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

Today’s Highlights January 13, 2026

Anavex Life Sciences Corp
Today, January 13, 2026, Anavex Life Sciences Corp. (AVXL) announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer’s disease (AD) across real‑world clinical settings. The multi-year program is funded by the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
January 13, 2026

Other Articles